Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Nov;8(22):1537.
doi: 10.21037/atm-20-3690.

IMPassionate about immunotherapy for TNBC: from change, to revolution and to cure?

Elena Vagia  1 , Massimo Cristofanilli  1
Affiliations
Editorial

IMPassionate about immunotherapy for TNBC: from change, to revolution and to cure?

Elena Vagia et al. Ann Transl Med. 2020 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-20-3690). MC declares personal fees from Pfizer, CytoDyn, Foundation Medicine and Lilly. EV has no conflicts of interest to declare.

Comment on

References

    1. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 2018;379:2108-21. 10.1056/NEJMoa1809615 - DOI - PubMed
    1. Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2020;21:44-59. 10.1016/S1470-2045(19)30689-8 - DOI - PubMed
    1. Adams S, Diéras V, Barrios CH, et al. Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. Ann Oncol 2020;31:582-9. 10.1016/j.annonc.2020.02.003 - DOI - PubMed
    1. Cortés J, André F, Gonçalves A, et al. IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. Future Oncol 2019;15:1951-61. 10.2217/fon-2019-0059 - DOI - PubMed
    1. Cortés J, Lipatov O, Im SA, et al. LBA21 - KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC). Annals of Oncology 2019;30:v859-v60. 10.1093/annonc/mdz394.010 - DOI